196 related articles for article (PubMed ID: 18753212)
1. CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.
Dutta J; Fan G; Gélinas C
J Virol; 2008 Nov; 82(21):10792-802. PubMed ID: 18753212
[TBL] [Abstract][Full Text] [Related]
2. Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins.
Gupta N; Delrow J; Drawid A; Sengupta AM; Fan G; Gélinas C
Cancer Res; 2008 Feb; 68(3):808-14. PubMed ID: 18245482
[TBL] [Abstract][Full Text] [Related]
3. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
Fan Y; Gélinas C
Oncogene; 2007 Jun; 26(27):4038-43. PubMed ID: 17173064
[TBL] [Abstract][Full Text] [Related]
4. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
[TBL] [Abstract][Full Text] [Related]
5. Peptidyl-prolyl isomerase Pin1 markedly enhances the oncogenic activity of the rel proteins in the nuclear factor-kappaB family.
Fan G; Fan Y; Gupta N; Matsuura I; Liu F; Zhou XZ; Lu KP; Gélinas C
Cancer Res; 2009 Jun; 69(11):4589-97. PubMed ID: 19458071
[TBL] [Abstract][Full Text] [Related]
6. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
Fan Y; Rayet B; Gélinas C
Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
[TBL] [Abstract][Full Text] [Related]
7. The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation.
Walker WH; Stein B; Ganchi PA; Hoffman JA; Kaufman PA; Ballard DW; Hannink M; Greene WC
J Virol; 1992 Aug; 66(8):5018-29. PubMed ID: 1321284
[TBL] [Abstract][Full Text] [Related]
8. Avian I kappa B alpha is transcriptionally induced by c-Rel and v-Rel with different kinetics.
Schatzle JD; Kralova J; Bose HR
J Virol; 1995 Sep; 69(9):5383-90. PubMed ID: 7636983
[TBL] [Abstract][Full Text] [Related]
9. Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein.
Chen C; Agnès F; Gélinas C
Mol Cell Biol; 1999 Jan; 19(1):307-16. PubMed ID: 9858554
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.
Liss AS; Bose HR
J Virol; 2002 May; 76(10):4928-39. PubMed ID: 11967310
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the v-Rel oncoprotein with NF-kappaB and IkappaB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo.
White DW; Pitoc GA; Gilmore TD
Mol Cell Biol; 1996 Mar; 16(3):1169-78. PubMed ID: 8622661
[TBL] [Abstract][Full Text] [Related]
12. AP-1 factors play an important role in transformation induced by the v-rel oncogene.
Kralova J; Liss AS; Bargmann W; Bose HR
Mol Cell Biol; 1998 May; 18(5):2997-3009. PubMed ID: 9566919
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.
Rayet B; Fan Y; Gélinas C
Mol Cell Biol; 2003 Mar; 23(5):1520-33. PubMed ID: 12588973
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of the inhibitor of apoptosis ch-IAP1 by v-rel and the proto-oncogene c-rel.
Kralova J; Liss AS; Bargmann W; Pendleton C; Varadarajan J; Ulug E; Bose HR
J Virol; 2002 Dec; 76(23):11960-70. PubMed ID: 12414938
[TBL] [Abstract][Full Text] [Related]
15. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
Starczynowski DT; Trautmann H; Pott C; Harder L; Arnold N; Africa JA; Leeman JR; Siebert R; Gilmore TD
Oncogene; 2007 Apr; 26(19):2685-94. PubMed ID: 17072339
[TBL] [Abstract][Full Text] [Related]
16. Activation of gga-miR-155 by reticuloendotheliosis virus T strain and its contribution to transformation.
Yao Y; Vasoya D; Kgosana L; Smith LP; Gao Y; Wang X; Watson M; Nair V
J Gen Virol; 2017 Apr; 98(4):810-820. PubMed ID: 28113043
[TBL] [Abstract][Full Text] [Related]
17. Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL.
Leeman JR; Weniger MA; Barth TF; Gilmore TD
Oncogene; 2008 Dec; 27(53):6770-81. PubMed ID: 18695674
[TBL] [Abstract][Full Text] [Related]
18. Activation of the TGF-β/Smad signaling pathway in oncogenic transformation by v-Rel.
Tiwari R; Bargmann W; Bose HR
Virology; 2011 Apr; 413(1):60-71. PubMed ID: 21345476
[TBL] [Abstract][Full Text] [Related]
19. The v-Rel oncoprotein complexes with new Rel- and RelA-related proteins in transformed cells.
Xu X; Gélinas C
Virology; 1995 Mar; 207(2):362-8. PubMed ID: 7886940
[TBL] [Abstract][Full Text] [Related]
20. Expression of v-rel in a replication competent virus: transformation and biochemical characterization.
Morrison LE; Boehmelt G; Beug H; Enrietto PJ
Oncogene; 1991 Sep; 6(9):1657-66. PubMed ID: 1656369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
